BAYN Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||€64.12|
|52 Week High||€67.99|
|52 Week Low||€43.91|
|1 Month Change||-4.73%|
|3 Month Change||18.59%|
|1 Year Change||13.85%|
|3 Year Change||14.36%|
|5 Year Change||-45.68%|
|Change since IPO||370.80%|
Recent News & Updates
Results: Bayer Aktiengesellschaft Exceeded Expectations And The Consensus Has Updated Its Estimates
Bayer Aktiengesellschaft ( ETR:BAYN ) investors will be delighted, with the company turning in some strong numbers with...
|BAYN||DE Pharmaceuticals||DE Market|
Return vs Industry: BAYN exceeded the German Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: BAYN exceeded the German Market which returned -12.4% over the past year.
|BAYN Average Weekly Movement||5.2%|
|Pharmaceuticals Industry Average Movement||6.5%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DE Market||10.8%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: BAYN is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BAYN's weekly volatility (5%) has been stable over the past year.
About the Company
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Fundamentals Summary
|BAYN fundamental statistics|
Is BAYN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BAYN income statement (TTM)|
|Cost of Revenue||€17.52b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 04, 2022
|Earnings per share (EPS)||2.24|
|Net Profit Margin||4.75%|
How did BAYN perform over the long term?See historical performance and comparison
3.1%Current Dividend Yield
Is Bayer undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAYN (€64.12) is trading below our estimate of fair value (€258.04)
Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAYN is poor value based on its PE Ratio (28.6x) compared to the German Pharmaceuticals industry average (22x).
PE vs Market: BAYN is poor value based on its PE Ratio (28.6x) compared to the German market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: BAYN is poor value based on its PEG Ratio (3.5x)
Price to Book Ratio
PB vs Industry: BAYN is good value based on its PB Ratio (1.7x) compared to the DE Pharmaceuticals industry average (2.7x).
How is Bayer forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAYN's forecast earnings growth (8.2% per year) is above the savings rate (-0.05%).
Earnings vs Market: BAYN's earnings (8.2% per year) are forecast to grow faster than the German market (7.8% per year).
High Growth Earnings: BAYN's earnings are forecast to grow, but not significantly.
Revenue vs Market: BAYN's revenue (1.7% per year) is forecast to grow slower than the German market (4.9% per year).
High Growth Revenue: BAYN's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAYN's Return on Equity is forecast to be high in 3 years time (20.4%)
How has Bayer performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAYN has a large one-off loss of €3.9B impacting its March 31 2022 financial results.
Growing Profit Margin: BAYN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BAYN's earnings have declined by 49.4% per year over the past 5 years.
Accelerating Growth: BAYN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BAYN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: BAYN's Return on Equity (5.9%) is considered low.
How is Bayer's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BAYN's short term assets (€38.2B) exceed its short term liabilities (€31.0B).
Long Term Liabilities: BAYN's short term assets (€38.2B) do not cover its long term liabilities (€57.2B).
Debt to Equity History and Analysis
Debt Level: BAYN's net debt to equity ratio (91.3%) is considered high.
Reducing Debt: BAYN's debt to equity ratio has increased from 51.8% to 113.1% over the past 5 years.
Debt Coverage: BAYN's debt is not well covered by operating cash flow (16.8%).
Interest Coverage: BAYN's interest payments on its debt are well covered by EBIT (8x coverage).
What is Bayer current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BAYN's dividend (3.12%) is higher than the bottom 25% of dividend payers in the German market (1.38%).
High Dividend: BAYN's dividend (3.12%) is low compared to the top 25% of dividend payers in the German market (4.31%).
Stability and Growth of Payments
Stable Dividend: BAYN's dividend payments have been volatile in the past 10 years.
Growing Dividend: BAYN's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (89.2%), BAYN's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (43.7%), BAYN's dividend payments are well covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Werner Baumann (59 yo)
Mr. Werner Baumann has been Chairman of Management Board and Chief Executive Officer at Bayer AG since May 1, 2016 and has been its Member of Management Board since January 1, 2010. Since January 1, 2020,...
CEO Compensation Analysis
Compensation vs Market: Werner's total compensation ($USD8.65M) is above average for companies of similar size in the German market ($USD4.70M).
Compensation vs Earnings: Werner's compensation has been consistent with company performance over the past year.
Experienced Management: BAYN's management team is considered experienced (4.7 years average tenure).
Experienced Board: BAYN's board of directors are seasoned and experienced ( 10.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bayer Aktiengesellschaft's employee growth, exchange listings and data sources
- Name: Bayer Aktiengesellschaft
- Ticker: BAYN
- Exchange: XTRA
- Founded: 1863
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €62.099b
- Shares outstanding: 982.42m
- Website: https://www.bayer.com
Number of Employees
- Bayer Aktiengesellschaft
- Kaiser-Wilhelm-Allee 1
- North Rhine-Westphalia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.